To Optimize Antenatal Management of Women With Pre Term Labor Using Amniocentesis
NCT04831086
Amniocentesis Affecting Fetus or Newborn, Female Urogenital Diseases and Pregnancy Complications
Barcelona, Spain
View Trial DetailsNCT Number: NCT00701350
The purpose of this study is to investigate the expression of protein biomarkers in cervical vaginal fluid in women with preterm premature rupture of membranes (PPROM)
Looking for future studies?
Notify Me18 year and older
Female
Observational
Banner Good Samaritan Hospital, Phoenix, Arizona, United States
Preterm premature rupture of the membranes (PPROM) prior to 37 weeks of gestation occurs in approximately 3% of all pregnancies and is associated with one-third of all preterm births (Mercer, 2003). While there are multiple possible etiologies of PPROM, intra-amniotic infection has been implicated as a major contributor, especially at early gestational ages where fetal and neonatal adverse sequelae are frequent (Yoon, et al. 2000). Micro-organisms are recovered from the amniotic fluid obtained by trans-abdominal amniocentesis in 25-40% of women at the time of presentation with PPROM (Simhan and Canavan 2005).
Significant risks to the fetus following PPROM include both complications related to prematurity and to infection or inflammation (ACOG Practice Bulletin 2007). Complications related to prematurity include respiratory distress, intraventricular hemorrhage, and necrotizing enterocolitis. IAI, both clinically apparent and occult, is an important and potentially preventable cause of cerebral white matter injury and cerebral palsy. Ideally, an early diagnosis of IAI in the setting of PPROM is important to allow timely treatment and intervention. Amniocentesis is successful from 40 - 72% of the time with PPROM (Garite, 1982, Blackwell and Berry, 1999). Despite the accuracy for determining infection and the feasibility of amniocentesis, the vast majority of clinicians are reluctant and/or unwilling to perform this procedure in this clinical setting (Capeless and Mead, (1987). There is therefore a critical need for a noninvasive test to identify patients with IAI and PPROM. Timely identification of these sub-clinically infected patients is critical in designing rationale and efficacious treatment strategies that may reduce the fetal and neonatal sequelae associated with PPROM.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 24 hours of amniotic membrane rupture to delivery
ProteoGenix, Inc.
Industry
Identification of Proteomic Markers of Intra-amniotic Infection (IAI) in Patients With Preterm Premature Rupture of Amniotic Membranes (PPROM)
Acronym: PPROM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04831086
Amniocentesis Affecting Fetus or Newborn, Female Urogenital Diseases and Pregnancy Complications
Barcelona, Spain
View Trial DetailsNCT04705935
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Aarhus, Denmark
View Trial DetailsNCT06653374
Abruptio Placentae, Asphyxia Neonatorum
Quito, Pichincha, Ecuador
View Trial DetailsNCT06396078
Chorioamnionitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Columbus, Ohio, United States
View Trial Details